Will combining GSK and Pfizer HIV businesses boost new therapies?
This article was originally published in Scrip
In an effort to become the market leader for HIV, GlaxoSmithKline and Pfizer have merged their antiretroviral portfolios to create a so-far unnamed London-based speciality company led by GSK's Dr Dominique Limet, with 11 marketed products and another six in the clinical pipeline.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.